Stem Cell Authority Ltd
Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. It specializes in the collection and cryogenic preservation of the hematopoietic stem cells from the umbilical cord blood; and the Miracle Mesenchymal stem cells from the Wharton's jelly inside the umbilical cord of a newborn child. The company's technology enables birt… Read more
Stem Cell Authority Ltd (SCAL) - Total Assets
Latest total assets as of May 2007: $2.72 Million USD
Based on the latest financial reports, Stem Cell Authority Ltd (SCAL) holds total assets worth $2.72 Million USD as of May 2007.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Stem Cell Authority Ltd - Total Assets Trend (2001–2009)
This chart illustrates how Stem Cell Authority Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Stem Cell Authority Ltd - Asset Composition Analysis
Current Asset Composition (August 2009)
Stem Cell Authority Ltd's total assets of $2.72 Million consist of 95.9% current assets and 4.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.1% |
| Accounts Receivable | $3.29 Million | 82.6% |
| Inventory | $17.72K | 0.4% |
| Property, Plant & Equipment | $79.70K | 2.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2009)
This chart illustrates how Stem Cell Authority Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Stem Cell Authority Ltd's current assets represent 95.9% of total assets in 2009, a decrease from 100.0% in 2001.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2009, up from -100.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 82.6% of total assets.
Stem Cell Authority Ltd Competitors by Total Assets
Key competitors of Stem Cell Authority Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xian International Medical Investment Co Ltd
SHE:000516
|
China | CN¥9.79 Billion |
|
Meinian Onehealth Healthcare Holdings Co Ltd
SHE:002044
|
China | CN¥19.57 Billion |
|
Hengkang Medical Group Co Ltd
SHE:002219
|
China | CN¥6.55 Billion |
|
TMC Life Sciences Bhd
KLSE:0101
|
Malaysia | RM1.12 Billion |
|
Optimax Holdings Sdn Bhd
KLSE:0222
|
Malaysia | RM146.00 Million |
|
Cengild Medical Berhad
KLSE:0243
|
Malaysia | RM218.07 Million |
|
DC HEALTHCARE HOLDINGS BERHAD
KLSE:0283
|
Malaysia | RM99.33 Million |
|
Raffles Medical Group Ltd
F:02M1
|
Germany | €1.49 Billion |
Stem Cell Authority Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Stem Cell Authority Ltd generates 0.83x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Stem Cell Authority Ltd generates $ 45.97 in net profit.
Stem Cell Authority Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.13 | 3.13 | - |
| Quick Ratio | 3.07 | 3.07 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $102.45K | $ 102.45K | - |
Stem Cell Authority Ltd - Advanced Valuation Insights
This section examines the relationship between Stem Cell Authority Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 486.5% |
| Total Assets | $3.99 Million |
| Market Capitalization | $1.84 USD |
Valuation Analysis
Below Book Valuation: The market values Stem Cell Authority Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Stem Cell Authority Ltd's assets grew by 486.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Stem Cell Authority Ltd (2001–2009)
The table below shows the annual total assets of Stem Cell Authority Ltd from 2001 to 2009.
| Year | Total Assets | Change |
|---|---|---|
| 2009-08-31 | $3.99 Million | +486.50% |
| 2008-08-31 | $679.57K | -10.70% |
| 2007-08-31 | $760.95K | +2818244.44% |
| 2006-08-31 | $27.00 | +80.00% |
| 2002-08-31 | $15.00 | 0.00% |
| 2001-08-31 | $15.00 | -- |